

DERREN HEALTHCARE PVT. LTD.

Plot No. #33, 35/p & 36/p XCELON Industrial Park, Lane besides Chak-de-India Weighbridge, Sarkhej-Bavla Highway Village: Vasna-Chacharvadi, Ahmedabad-382 213, Gujarat (India)

CERTIFICATE OF ANALYSIS

(FINISHED PRODUCT)

Name of Product	Citicoline Injection IP 250mg/ml(CITISTROKE 4)		
Batch No.	AU24001	A.R. No.	FP/24/0050
Mfg. Date	06/24	Exp. Date	05/26
Sampled Qty.	41 Nos.	Date of Analysis	27/06/24
Batch Size	100 Ltr.	Date of Release	13/07/24
Container Type	Clear Glass Ampoule	Fill Volume	4.2 ml
Mfg. Lic. No.	G/28/1862		

Sr. Result Test Specification No. Clear, Colourless solution free from Clear, Colourless or almost colourless 1 Description visible particles and fibers. solution free from visible particles and fibers. 2 Extractable volume NLT 4.0 ml 4.0 ml 3 Identification In the Assay, the principal peak in the In the Assay, the principal peak in the chromatogram obtained with the test chromatogram obtained with the test Identification A by 3.1 solution is correspond to the peak in the solution should be correspond to the **HPLC** chromatogram obtained with peak in the chromatogram obtained reference solution with the reference solution 6.3 to 8.0 4 pH 7.2 5 **Related Substances** 0.08 % 5 '-cytidylic acid NMT 1.5% 5.1 Any other secondary 0.04 % 5.2 NMT 0.5% impurity Total impurities other 0.04% 5.3 NMT 2.0% than 5 '-cytidylic acid Bacterial endotoxin 6 Less than 0.175 Eu/mg NMT 0.175 EU/mg of Citicoline Particulate matter 7 The solution is free from particles that The solution should be free from 7.1 By Visual Inspection is observed by inspection with the particles that can be observed by unaided eye. inspection with the unaided eye. Sub visible particle by LPC By Light Obscuration >10 microns= 814.40/Container 7.2 ≥10 microns=NMT 6000/Container Method > 25 Microns= 40.00/Container > 25 Microns=NMT 600/Container 8 Sterility test Sterile Should be sterile 9 Assay Each ml Contains: 90.0% to 110.0% of the labeled amount 9.1 Citicoline Sodium IP eq. 101.8% of Citicoline to Citicoline 250 mg

Conclusion: The above sample complies as per IP specification.

In the opinion of the undersigned the sample referred to above is of standard / not of standard quality as defined in the act and the rules made there under for the reasons given above.

Approved By
GLE ASSUBANCE TO
QA MANAGER

Format No.: DHPL/QCD/023/F23/00

Page No.: 1 of 1